Comparative Pharmacology
Head-to-head clinical analysis: LANREOTIDE ACETATE versus SANDOSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANREOTIDE ACETATE versus SANDOSTATIN.
LANREOTIDE ACETATE vs SANDOSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lanreotide is a synthetic octapeptide analog of somatostatin. It binds predominantly to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. It also reduces secretion of gastrointestinal hormones such as serotonin and gastrin.
Synthetic octapeptide analog of somatostatin with longer half-life. Inhibits growth hormone (GH), glucagon, and insulin secretion. Reduces splanchnic blood flow and suppresses serotonin release from neuroendocrine tumors.
90 mg subcutaneously every 4 weeks
Subcutaneous: 50-100 mcg every 8-12 hours. Intravenous bolus: 50 mcg, then continuous infusion 25-100 mcg/hour for acute variceal bleeding.
None Documented
None Documented
Terminal elimination half-life: 23-30 hours following subcutaneous administration; prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life: 1.7–1.9 hours (subcutaneous); prolonged in hepatic impairment (up to 2.6 h). After intravenous bolus, biphasic elimination with t½ α ~0.2 h and t½ β ~1.5 h.
Primarily renal (approximately 60-70% of dose excreted unchanged in urine), with biliary/fecal elimination accounting for about 30%.
Renal: ~32% unchanged; biliary/fecal: ~66% as metabolites; total clearance ~160 mL/min.
Category C
Category C
Somatostatin Analog
Somatostatin Analog